ProMIS Neurosciences Inc PMN

Biogen update

[retiredcop]

https://www.fiercepharma.com/marketing/biogen-piles-more-long-term-aduhelm-data-linking-biomarker-alzheimers-clinical-benefit

[M101]

LMAO, that is some NATO level spin you found there. https://endpts.com/scoop-biogen-will-finally-publish-its-phiii-results-for-aduhelm/

[retiredcop]

Bad news for Biogen: Medicare didn't change its mind.   After accepting more than 10,000 bits of input during a public comment period over the last three months, the Centers for Medicare & Medicaid Services held to its original decision to limit coverage of the company’s Alzheimer’s disease treatment Aduhelm—and other drugs like it—to clinical trials

[retiredcop]

CNN)Medicare will restrict coverage of the controversial and costly Alzheimer's drug Aduhelm to those enrolled in qualifying clinical trials, the Centers for Medicare and Medicaid Services announced Thursday. The final decision, which follows a proposed policy released in January, will have far-reaching consequences for millions of Alzheimer's patients and tens

[M101]

Seemed like a formality at this point. The FDA can't take any more stink right now so killing Medicare will just have to wait for war profiteering to take the spotlight off pharma profiteering.  But the decision said nothing about the medical strategy, the door remains wide open for Promis.  “Monoclonal antibodies directed against amyloid that are approved by FDA for the treatment

[retiredcop]

Not sure if anyone else picked up on what was said in this last article.  It is expected to restrict the number of people who can receive the medication. The coverage policy would also apply to other drugs in this class -- monoclonal antibodies that target amyloid, or plaque, for the treatment of Alzheimer's disease -- that the Food and Drug Administration may approve in the future.

[M101]

This post has been removed in accordance with Community Policy

[M101]

This post has been removed in accordance with Community Policy

[azzymaa]

This post has been removed in accordance with Community Policy

[retiredcop]

https://theconversation.com/the-fda-approved-a-new-drug-to-treat-alzheimers-but-medicare-wont-always-pay-for-it-a-doctor-explains-what-researchers-know-about-biogens-aduhelm-179177

[retiredcop]

We might have a situation where our PMBN310 clinicals will be conducted in countries outside " Lets Make America Great Again"  I would say Canada and South America and the UK would be suitable locations..  https://www.alzforum.org/news/community-news/drilling-down-cms-aduhelm-decision-primer

[M101]

Trials targeted to avoid the CMS controversy would be a mistake, branding as anti-amyloid is our problem. The rebranding is underway, but that stink won't wash off while Gene is running the show.